Sutro Biopharma (STRO) Non-Current Debt (2018 - 2022)

Sutro Biopharma (STRO) has 5 years of Non-Current Debt data on file, last reported at $3.8 million in Q4 2022.

• For the quarter ending Q4 2022, Non-Current Debt fell 76.04% year-over-year to $3.8 million; the trailing twelve-month figure through Dec 2022 stood at $3.8 million (down 76.04% YoY), and the FY2022 full-year result was $3.8 million, down 76.04% from the prior year.
• Non-Current Debt slipped to $3.8 million in Q4 2022, from $6.8 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $24.7 million in Q1 2021 to a low of $3.8 million in Q4 2022.
• A 5-year average of $14.6 million and a median of $12.1 million in 2018 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 343.84% in 2020 and slumped 76.04% in 2022, its largest moves.
• Tracing STRO's Non-Current Debt over 5 years: stood at $10.0 million in 2018, then decreased by 11.24% to $8.9 million in 2019, then surged by 176.53% to $24.5 million in 2020, then plunged by 35.88% to $15.7 million in 2021, then tumbled by 76.04% to $3.8 million in 2022.
• Business Quant data shows STRO's Non-Current Debt at $3.8 million in Q4 2022, $6.8 million in Q3 2022, and $9.8 million in Q2 2022.